Ozempic Generic Peptide Market Trends: Brand Competition, Technical Pros & Cons, and Industry Data Analysis
Published: 13 7 月, 2026 00:07
Author: Joshua Nelson
Abstract: The Ozempic generic peptide market is driven by surging demand for GLP-1 agonists, with semaglutide generics capturing 40% of the 2024 market share. Brand competition centers on Novo Nordisk’s patent expiry vs. Chinese manufacturers offering 60-80% cost reduction. Technical pros include enhanced bioavailability via lipidated peptides; cons involve purity variability (95-99%) and cold-chain logistics costs. Industry data projects a 15.2% CAGR through 2030, with factory GMP certification and third-party HPLC purity reports critical for selection.